# COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension

> **NCT00273052** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 514 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Carvedilol Phosphate modified release formulation
- **DRUG:** metoprolol succinate

## Key facts

- **NCT ID:** NCT00273052
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-05
- **Primary completion:** 2007-12-01
- **Final completion:** 2007-12-28
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2018-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00273052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00273052, "COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00273052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*